About us

Want to know more?

We Are ERBC

A leading preclinical CRO

ERBC is a leading independent Contract Research Organization in Europe specialized in non-clinical studies, from preclinical proof-of-concept to market, in line with the current international regulatory requirements.

Comprehensive development of all products

We offer GLP and non GLP studies together with NHP breeding to pharmaceutical, biotech, chemical, food, veterinarian and medical industries, worldwide.

History

Step by step
a Group

Since November 2019, ERBC is building the leading
independent non-clinical CRO in Europe, through:

The acquisition of talents,
The development of expertise,
Internal development of capacities/models
M&A and strategic partnerships

Nov
2019

ERBC creation

Following the acquisition of RTC (Italy) by CERB, >50 years of experience in preclinical regulatory development of drugs & chemicals

Dec
2020

Acquisition of BIOPRIM

Acquisition of BIOPRIM Baziège, 31, for securing NHP supply

Jul
2022

Acquisition of NOVAXIA

Acquisition of NOVAXIA St Laurent-Nouan, 41  for solidifying histopathology expertise

Dec
2022

Acquisition of ONCOFACTORY

Acquisition of ONCOFACTORY, Lyon, 69, for selecting anticancer drugs and patients for the clinic

Jul
2023

Acquisition of VOXCAN

Acquisition of VOXCAN, Dommartin, 69, for imaging and biosafety confinement laboratories (BSL2 &3)

Location

Locations

ERBC is currently organized around 6 sites in Europe. Click on each location (point) to access more details.

Team

Board management

At ERBC, our Board and Management Team is composed of experienced leaders committed to driving innovation and excellence in preclinical research and regulatory toxicology. With deep expertise in science, business strategy, and regulatory frameworks, our leadership team ensures that ERBC remains a trusted partner for the pharmaceutical, chemical, agrochemical, cosmetic, and medical device industries.

Learn more Learn more

Team

Animal welfare & ethics

At ERBC, we understand the importance of responsibility in every step of our processes. As part of our ongoing commitment to Animal Welfare and Ethics, we adhere to the core principles of Replacement, Reduction, and Refinement (3Rs) and integrate Responsibility and Rehoming, as 4th and 5th Rs, to ensure animal well-being in our everyday approach to advancing science.

Learn more Learn more

Team

Total quality

At ERBC, we are committed to providing the highest quality preclinical and clinical research services. We follow regulatory standards and use a Total Quality Approach to create a unified, simple, strong, and integrated quality management system across all ERBC sites and activities. Our transformation is guided by a risk-based approach, improving our predictive capabilities, agility, and efficiency.

Learn more Learn more

Team

ESG-CSR

At ERBC, we are committed to sustainable development and corporate responsibility. Our CSR strategy is focused on three key pillars: Social Responsibility, Environmental Stewardship, and Governance Excellence. These pillars guide our actions and drive positive impact for our employees, clients, suppliers, and the environment. Our goal is to integrate sustainability into everything we do, ensuring a healthier future for generations to come.

Learn more Learn more